| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 06/07/2001 | CA2747954A1 Phosphonate compounds |
| 06/07/2001 | CA2393265A1 Novel heterocyclic compounds and salts thereof and medicinal use of the same |
| 06/07/2001 | CA2393217A1 Oxazolidinone derivatives |
| 06/07/2001 | CA2393190A1 Substituted oxazoles and thiazoles derivatives as hppar alpha activators |
| 06/07/2001 | CA2393179A1 Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof |
| 06/07/2001 | CA2392979A1 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline crystal |
| 06/07/2001 | CA2392931A1 Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents |
| 06/07/2001 | CA2392717A1 Cytokine receptor-like polynucleotides, polypeptides, and antibodies |
| 06/07/2001 | CA2392039A1 New tri-substituted phenyl derivatives and analogues |
| 06/07/2001 | CA2392038A1 Crystalline form of (s)-2 ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid |
| 06/07/2001 | CA2392029A1 Comminuted form of (s)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl] propanoic acid |
| 06/07/2001 | CA2391402A1 Masp-3, a complement-fixing enzyme, and uses for it |
| 06/07/2001 | CA2390786A1 Compositions and methods for the treatment of immune related diseases |
| 06/07/2001 | CA2389368A1 Compounds, compositions, and methods for stimulating neuronal growth and elongation |
| 06/07/2001 | CA2388239A1 Neuroprotective agents and methods related thereto |
| 06/07/2001 | CA2327638A1 Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications |
| 06/07/2001 | CA2327575A1 Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications |
| 06/06/2001 | EP1104758A1 Acetylene derivatives as anti-inflammatory/analgesic agents |
| 06/06/2001 | EP1104440A1 A g-protein coupled 7tm receptor (axor-1) |
| 06/06/2001 | EP1104422A1 Phenyl xanthine derivatives |
| 06/06/2001 | EP1104421A1 3-(4-amino-5-ethylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1h-pyrazolo 3,4-b]pyridine |
| 06/06/2001 | EP1104412A1 Tace inhibitors |
| 06/06/2001 | EP1104410A1 New carboxylic acid derivatives carrying keto side-chains, their production and their use as endothelin-receptor antagonists |
| 06/06/2001 | EP1104408A2 Drug targeting |
| 06/06/2001 | EP1104403A1 Hydroxy pipecolate hydroxamic acid derivatives as mmp inhibitors |
| 06/06/2001 | EP1104304A1 Multivalent avb3 and metastasis-associated receptor ligands |
| 06/06/2001 | EP1104293A1 Regulation of substrate activity |
| 06/06/2001 | EP1104292A2 Treatment of vasodilatory headache |
| 06/06/2001 | EP1104236A1 Transdermally delivered aspirin |
| 06/06/2001 | EP0889891B1 4-[(thien-2-yl)methyl]imidazole derivatives having alpha2-adrenoceptor agonistic activity |
| 06/06/2001 | EP0676961B1 Use of macrolides for the treatment of cerebral ischemia |
| 06/06/2001 | EP0673426B1 Platelet-activating factor acetylhydrolase |
| 06/06/2001 | CN1298411A Caspase-8 interacting proteins |
| 06/06/2001 | CN1298406A Condensed thienopyrimidines with phosphodiesterase-V inhibiting action |
| 06/06/2001 | CN1298404A Inhibitors of phospholipase A2 |
| 06/06/2001 | CN1298403A Process for making 1,3-disubstituted-4-oxocyclic ureas |
| 06/06/2001 | CN1298402A Process for making 1,3-disubstituted-4-oxocyclic ureas |
| 06/06/2001 | CN1298394A Aryl fused azapolycyclic compounds |
| 06/06/2001 | CN1298393A Quinoline derivatives |
| 06/06/2001 | CN1298386A N-substituted aminotetralins as ligands for the neuropeptide YY5 receptor useful in the treatment of obesity and other disorders |
| 06/06/2001 | CN1298309A Method for treating painful conditions of the anal region and compositions therefor |
| 06/06/2001 | CN1298303A Stable compositions comprising levosimendan and alginic acid |
| 06/06/2001 | CN1298302A Topical administration of oxazolidinones for transdermal delivery |
| 06/06/2001 | CN1298300A Fire-resistant non-explosive solid mixtures containing nitroglycerine and water-free lactose |
| 06/06/2001 | CN1298298A Periadventitial delivery device |
| 06/06/2001 | CN1297765A Tibetans medicine for treating cardiac and cerebral vascular disease and white pulse disease |
| 06/06/2001 | CN1297763A Gastrodia elata tea for hypertension |
| 06/06/2001 | CN1297743A Buccal tablet of Qingqian Willow leaf |
| 06/06/2001 | CN1297702A Gamma-linolenic acid replenishing additive for food, medicine and cosmetics |
| 06/06/2001 | CN1066734C Novel intermediates and their use to prepare N,N'-bridged bisindolylmaleimides |
| 06/06/2001 | CN1066727C Anti-migraine indole derivative salts |
| 06/06/2001 | CN1066725C Optically active thiazolidinone derivatives |
| 06/06/2001 | CN1066720C Process for producing pharmaceutically active CNS compounds |
| 06/06/2001 | CN1066719C Process for producing pharmaceutically active CNS compounds |
| 06/06/2001 | CN1066718C Substituted aryloxy-alkyl diamines and its producing process and use |
| 06/06/2001 | CN1066625C Therapeutical use for benzopyran derivative |
| 06/06/2001 | CN1066624C Dry mix formulation for bisphosphonic acids |
| 06/06/2001 | CA2328553A1 Novel derivatives (dihydro)benzoxazine and (dihydro)benzothiazine substitutes, process for preparing them and pharmaceutical compositions containing them |
| 06/05/2001 | US6242644 N-(4-carbamimidoyl-phenyl)-glycine derivatives |
| 06/05/2001 | US6242637 Substituted heterocylic compounds, method of preparing them and pharmaceutical compositions in which they are present |
| 06/05/2001 | US6242601 Heterocyclic sulfamides |
| 06/05/2001 | US6242490 Use of creatine |
| 06/05/2001 | US6242482 Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure |
| 06/05/2001 | US6242479 Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of disease |
| 06/05/2001 | US6242473 Administering histamine |
| 06/05/2001 | US6242459 Substituted bis-acridines and related compounds as CCR5 receptor ligands, anti-inflammatory agents and anti-viral agents |
| 06/05/2001 | US6242455 Inhibiting a matrix metalloprotease associated disease |
| 06/05/2001 | US6242444 5-(2,3-dihydro-5-(4-methylpiperazin-1-ylsulfonyl)-7-benzofuryl )-1-methyl-3-propyl-6,7-dihydro-1h-pyrazolo(4,3-d)pyrimidin-7-one, for example; treatment of inter alia erectile dysfunction. |
| 06/05/2001 | US6242438 3-Azetidinylalkylpiperidines or -pyrrolidines as tachykinin antagonists |
| 06/05/2001 | US6242432 Antihypertensive activity, antihypersensitive activity; treatment of cardiovascular disease |
| 06/05/2001 | US6242422 (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases |
| 06/05/2001 | US6242419 Genes encoding proteins expressed in lymph node stromal cells from flaky skin (fsn-/-) mice and their use in therapy. |
| 06/05/2001 | US6242238 Nucleotide sequence which codes for heparinase; drug screening for antimetastasis/antinflammatory agents, angiogenesis inhibitors, wound healing agents; treatment for angioplasty-induced restenosis and atherosclerosis |
| 06/05/2001 | CA2198852C Parenteral solutions containing 7-halo-1,2,3,4-tetrahydro-3-aryl-6-quinazoline sulfonamides |
| 06/05/2001 | CA2046051C 2,6-di-alkyl-4-silyl-phenols as antiatherosclerotic agents |
| 05/31/2001 | WO2001038878A2 Pin1 as a marker for abnormal cell growth |
| 05/31/2001 | WO2001038503A2 Novel human protein kinases and protein kinase-like enzymes |
| 05/31/2001 | WO2001038486A2 Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies |
| 05/31/2001 | WO2001038397A1 N-alkylated peptides having antiangiogenic activity |
| 05/31/2001 | WO2001038395A1 Oxidized apolipoproteins and methods of use |
| 05/31/2001 | WO2001038347A2 Peptides having antiangiogenic activity |
| 05/31/2001 | WO2001038344A2 Modulation of signal transduction |
| 05/31/2001 | WO2001038325A1 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| 05/31/2001 | WO2001038324A2 Imidazole derivatives and their use as raf kinase inhibitors |
| 05/31/2001 | WO2001038323A1 Pyrazinone thrombin inhibitors |
| 05/31/2001 | WO2001038320A1 Vitamin d analogues |
| 05/31/2001 | WO2001038316A2 Sulfonyl oxazole amines and their use as 5-ht6 receptor ligands |
| 05/31/2001 | WO2001038315A1 Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes |
| 05/31/2001 | WO2001038314A1 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors |
| 05/31/2001 | WO2001038313A1 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p39 kINASE INHIBITORS |
| 05/31/2001 | WO2001038312A1 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p38 KINASE INHIBITORS |
| 05/31/2001 | WO2001038311A2 Pyrimidine derivatives as selective inhibitors of cox-2 |
| 05/31/2001 | WO2001038310A1 2-arylquinoline derivatives, preparation and therapeutic use thereof |
| 05/31/2001 | WO2001038309A1 β-AMINO ACID-, ASPARTIC ACID- AND DIAMINOPROPIONIC-BASED INHIBITORS OF FACTOR Xa |
| 05/31/2001 | WO2001038305A2 Novel il-8 receptor antagonists |
| 05/31/2001 | WO2001038303A2 Vitamin d analogues |
| 05/31/2001 | WO2001038295A1 Sphingosine derivatives |
| 05/31/2001 | WO2001037868A1 Assays and therapies for latent viral infection |
| 05/31/2001 | WO2001037859A2 Pharmaceutical compositions containing compounds which increase or decrease tmtnf levels |
| 05/31/2001 | WO2001037857A1 Major intrinsic protein (mip)-like polynucleotides, polypeptides, and antibodies |